SRTS Form 4: CEO Sardano increases direct stake to 1.2M shares

Q: What is the relationship of the reporting person to Sensus Healthcare (SRTS)?

The reporting person, Joseph C. Sardano , is both a director and an officer of Sensus Healthcare, serving as its Chief Executive Officer .

Q: What type of SEC form was filed for this Sensus Healthcare insider transaction?

The transaction was reported on Form 4 , which discloses changes in beneficial ownership of Sensus Healthcare equity securities by an insider.

Q: Was the Sensus Healthcare CEO’s ownership reported as direct or indirect?

The Form 4 shows that the 1,200,293 shares of Sensus Healthcare common stock are held with direct (D) ownership by Joseph C. Sardano.

Filing Impact

(High)

Filing Sentiment

(Positive)

Form Type

Rhea-AI Filing Summary

Sensus Healthcare, Inc. (SRTS) reported an insider stock purchase by its Chief Executive Officer and director, Joseph C. Sardano. On 11/18/2025, he acquired 25,000 shares of Sensus Healthcare common stock in an open-market purchase transaction coded "P" at an average price of $4.03 per share, as noted in the explanation that this figure represents the average price per share.

Following this transaction, Sardano beneficially owns 1,200,293 shares of Sensus Healthcare common stock in direct ownership. The filing is made on Form 4 as a report by one reporting person in his capacity as both director and Chief Executive Officer of the company.

Insider Trade Summary

Net Buyer: 25,000 shares

Net Buy 1 txn

Insider Sardano Joseph C

Role CHIEF EXECUTIVE OFFICER

Bought 25,000 shs ($101K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	25,000	$4.03	$101K

Holdings After Transaction: Common Stock — 1,200,293 shares (Direct)

Footnotes (1)

F1. Represents the average price per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 11/19/2025 - 09:34 AM

FAQ

What insider transaction did Sensus Healthcare (SRTS) report on this Form 4?

The Form 4 reports that Chief Executive Officer and director Joseph C. Sardano purchased 25,000 shares of Sensus Healthcare common stock on 11/18/2025.

At what price were the SRTS shares acquired by the CEO?

The 25,000 Sensus Healthcare shares were acquired at an average price of $4.03 per share, which the filing notes represents the average price per share.

How many Sensus Healthcare (SRTS) shares does the reporting person own after the transaction?

After the reported purchase, Joseph C. Sardano beneficially owns 1,200,293 shares of Sensus Healthcare common stock in direct ownership.

What is the relationship of the reporting person to Sensus Healthcare (SRTS)?

The reporting person, Joseph C. Sardano, is both a director and an officer of Sensus Healthcare, serving as its Chief Executive Officer.

What type of SEC form was filed for this Sensus Healthcare insider transaction?

The transaction was reported on Form 4, which discloses changes in beneficial ownership of Sensus Healthcare equity securities by an insider.

Was the Sensus Healthcare CEO’s ownership reported as direct or indirect?

The Form 4 shows that the 1,200,293 shares of Sensus Healthcare common stock are held with direct (D) ownership by Joseph C. Sardano.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sardano Joseph C

(Last)

(First)

(Middle)

851 BROKEN SOUND PARKWAY NW STE 215

(Street)

BOCA RATON

33487

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Sensus Healthcare, Inc. [ SRTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF EXECUTIVE OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/18/2025		P		25,000	A	$4.03⁽¹⁾	1,200,293	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents the average price per share.

	/s/ Joseph C. Sardano	11/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR